4.6 Letter

Seroresponse to Third Doses of SARS-CoV-2 Vaccine Among Patients Receiving Maintenance Dialysis

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Letter Urology & Nephrology

Seroresponse to SARS-CoV-2 Vaccines Among Maintenance Dialysis Patients

Caroline M. Hsu et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Letter Medicine, General & Internal

Antibody Response to a Fourth Messenger RNA COVID-19 Vaccine Dose in Kidney Transplant Recipients: A Case Series

Sophie Caillard et al.

ANNALS OF INTERNAL MEDICINE (2022)

Article Urology & Nephrology

Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months

Caroline M. Hsu et al.

Summary: This study evaluated the antibody response over time in patients receiving maintenance dialysis after SARS-CoV-2 vaccination. The study found that patients with a history of COVID-19 had a decline in antibody titers over time. Different vaccine types had varying rates of decline in antibody titers, with Ad26.COV2.S (Janssen) showing the lowest response.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Review Urology & Nephrology

Secondary Immunodeficiency Related to Kidney Disease (SIDKD)-Definition, Unmet Need, and Mechanisms

Stefanie Steiger et al.

Summary: Kidney disease is a significant risk factor for poor outcomes in COVID-19 and other infections. Infection is also a common cause of death in patients with kidney disease. Despite this, there is limited understanding and research on the secondary immunodeficiency related to kidney disease (SIDKD). This study aims to raise awareness of SIDKD as a critical unmet medical need, reviewing its epidemiology and discussing the abnormal immunophenotype in kidney disease patients. It proposes a definition for SIDKD and explores the pathogenic mechanisms involved, including the role of FGF23 levels, hyperuricemia, and changes in the secretome of the gut microbiota in kidney disease. The ultimate goal is to develop therapeutics that can improve immune responses and reduce mortality from infections in kidney disease patients.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2022)

Article Multidisciplinary Sciences

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Ottavia Prunas et al.

Summary: Existing evidence has established the effectiveness of vaccines against COVID-19 at the individual level. However, there is limited research on the effectiveness of vaccines in preventing transmission. A study conducted in Israel found that the BNT162b2 vaccine significantly reduced the risk of household transmission of SARS-CoV-2. However, the vaccine's effectiveness in reducing infectiousness among individuals who are already infected was lower during the 10 to 90 days after the second dose. Overall, the total vaccine effectiveness against COVID-19 was high, but it decreased over time due to waning immunity and the emergence of the Delta variant.

SCIENCE (2022)

Article Urology & Nephrology

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis

Ilias Bensouna et al.

Summary: The effectiveness of a third dose of the BNT162b2 vaccine in patients undergoing dialysis treatment was investigated, and it was found that the third dose significantly increased antibody levels.

AMERICAN JOURNAL OF KIDNEY DISEASES (2022)

Article Urology & Nephrology

COVID-19 Infection Among US Dialysis Patients: Risk Factors and Outcomes From a National Dialysis Provider

Caroline M. Hsu et al.

AMERICAN JOURNAL OF KIDNEY DISEASES (2021)

Article Medical Laboratory Technology

Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers

Christian Irsara et al.

Summary: The clinical performance of the Siemens sCOVG assay was evaluated, with specificity of 99.4% and sensitivity of 90.5%. S1-RBD antibody levels showed good correlation with virus neutralization titers, serving as a surrogate for neutralizing capacity. Levels of S1-RBD IgG increase with age, with significantly higher levels observed in hospitalized COVID-19 patients compared to outpatients.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2021)

Article Medical Laboratory Technology

Performance Evaluation of the Siemens SARS-CoV-2 Total Antibody and IgG Antibody Test

Lisa Florin et al.

Summary: This study evaluated the performance of 2 commercially available SARS-CoV-2 antibody assays and found both tests to have acceptable performance. Although Seroconversion occurred earlier with the COV2T test, both tests showed a sensitivity approaching 100% after 14 days of symptom onset.

LABORATORY MEDICINE (2021)

Letter Urology & Nephrology

Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis

Didier Ducloux et al.

KIDNEY INTERNATIONAL (2021)

Article Transplantation

High immunogenicity of a messenger RNA-based vaccine against SARS-CoV-2 in chronic dialysis patients

Nathalie Longlune et al.

Summary: For dialysis patients, the immunogenicity of anti-SARS-CoV-2 mRNA vaccine is high, and a two-dose vaccination is recommended with a possible third dose for non-responders. Patients awaiting kidney transplantation should be offered the vaccine before transplantation.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)

Letter Medicine, General & Internal

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England

Ross J. Harris et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Article Immunology

Evidence for antibody as a protective correlate for COVID-19 vaccines

Kristen A. Earle et al.

Summary: The study found a strong correlation between antibody titers and efficacy when assessing different COVID-19 vaccines, supporting the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.

VACCINE (2021)

Article Urology & Nephrology

Humoral response to a third injection of BNT162b2 vaccine in patients on maintenance haemodialysis

Marine Dekervel et al.

Summary: The study revealed that a third dose of BNT162b2 vaccine enhanced the humoral response against SARS-CoV-2 in maintenance dialysis patients, leading to seroconversion in more non-responders.

CLINICAL KIDNEY JOURNAL (2021)

Article Transplantation

COVID-19 vaccination in haemodialysis patients: good things come in threes...

Luc Frantzen et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2021)